Clinical trial · Observational
Comparative Analysis of SUV Measurements Using Different Correction Methods in Oncological PET/CT Imaging.
NCT07306975CI-TRIAL-00099754not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
-To measure SUVs by using different correction methods in oncological PET/CT imaging.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer Patients Referred to do PET/CT Study | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PET/CT with 18-FDG | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- -To measure SUVs by using different correction methods in oncological PET/CT imaging.
- timeFrame
- 1/12/2025 to 1/10/2027
- description
- -To compare between SUV measurements in the tumor and liver using different standardizing parameters such as: body weight, lean body mass and body surface area.
Secondary outcomes (1)
- measure
- To determine if SUVbsa is more accurate than SUVbw in obese patients.
- timeFrame
- 1/12/2025 to 1/10/2027
- description
- -To determine if ''normalization of FDG uptake for the body surface area'' (SUVbsa) is independent of the patient's body size and is more reliable than SUVbw.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Cancer patients (\> 18 years old) referred to nuclear medicine unit to do F18-FDG PET/CT study. Exclusion Criteria: * Patients \< 18 years old. * Patients with increased FDG uptake on tissue associated with non-malignant causes such as diffuse bone marrow FDG uptake or inflammatory. * Patients with extensive metastasis.
References
Publications (4)
- RESULTKim CK, Gupta NC, Chandramouli B, Alavi A. Standardized uptake values of FDG: body surface area correction is preferable to body weight correction. J Nucl Med. 1994 Jan;35(1):164-7. PMID 8271040
- RESULTNakaichi T, Funamoto K, Yamashita S, Yamamoto H, Yokoyama K. Clinical Usefulness of Standardized Uptake Value Normalized to Lean Body Mass Measured Using a Body Composition Analyzer. Cureus. 2025 May 30;17(5):e85089. doi: 10.7759/cureus.85089. eCollection 2025 May. PMID 40589668
- RESULTAzmi NHM, Suppiah S, Liong CW, Noor NM, Said SM, Hanafi MH, et al. Reliability of standarized uptake value normalized to lean body mass using the liver as a reference organ, in contrast-enhanced 18F-FDG PET/CT imaging. Radiography. 2018;24(2):112-117. doi:10.1016/j.radi.2017.09.006.
- RESULTAhmed A, Ali M, Salah H, Eisa RE, Mohieldin H, Omer H, et al. Evaluation of uptake values of FDG: Body surface area Vs. body weight correction. Radiat Phys Chem. 2022;201:110482. doi:10.1016/j.radphyschem.2022.110482 .